Brief: MPP and Roche Sign Voluntary Licence Agreement For Baloxavir Marboxil
18/05/2026 17:17
May 18 (Reuters) - Medicines Patent Pool: MEDICINES PATENT POOL: MPP ROCHE ANNOUNCED SIGNING OF VOLUNTARY LICENCE AGREEMENT FOR BALOXAVIR MARBOXIL MPP: LAUNCHING EXPRESSION OF INTEREST TO FIND QUALIFIED GENERIC MANUFACTURERS WITH NEEDED CAPACITIES FOR DEVELOPMENT SUPPLY OF BALOXAVIR MARBOXIL MPP: AGREEMENT TO ENABLE GENERIC MANUFACTURERS TO DEVELOP, PRODUCE SUPPLY BALOXAVIR IN 129 LOW- AND MIDDLE-INCOME COUNTRIES Further company coverage: ROPC.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza